The NeXT Dx test is a comprehensive genomics tumor profiling test based on whole exome and transcriptome sequencing. It is intended for profiling a solid tumor’s genomic and molecular characteristics using clinical-grade, next-generation sequencing (NGS) technology to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), fusions, MSI and exome-wide “true” tumor mutational burden (TMB). Germline mutations are also reported as incidental findings from sequencing of the matched normal sample. In addition, mutations in genes involved in homologous recombination repair (HRR) are highlighted when identified.